Loading…
Loading…
EQUITY / NASDAQ · XNCM
Bionexus Gene Lab Corp.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.2172 USD · -4.1575%
Observed: Oct 2, 2026, 10:29 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.27 USD · Volume 2,539
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 76,156 USD | 2,260,253 USD | -96.63% |
| Operating profit | -282,396 USD | -611,293 USD | — |
| Net income | -286,451 USD | -616,172 USD | — |
| Cash and cash equivalents | 1,232,658 USD | — | — |
| Total liabilities | 947,981 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 1,232,658 USD | — | — | 2,383,369 USD | 2,486,383 USD | — | — | — |
| Gross profitIncome statement | 12,982 USD | 12,192 USD | — | — | 1,085,217 USD | 377,685 USD | 1,089,200 USD | 368,022 USD |
| Net incomeIncome statement | -286,451 USD | -830,026 USD | -543,575 USD | — | -2,984,607 USD | -708,991 USD | -1,948,490 USD | -616,172 USD |
| Operating profitIncome statement | -282,396 USD | -822,886 USD | — | — | -2,965,065 USD | -702,509 USD | -1,932,220 USD | -611,293 USD |
| RevenueIncome statement | 76,156 USD | 98,998 USD | — | — | 7,424,911 USD | 2,543,823 USD | 6,941,151 USD | 2,260,253 USD |
| Total assetsBalance sheet | 8,726,423 USD | — | — | 9,252,784 USD | 9,252,784 USD | 7,621,228 USD | — | — |
| Total equityBalance sheet | 7,778,442 USD | — | 8,093,253 USD | 8,614,928 USD | 8,614,928 USD | 6,816,262 USD | — | 7,522,037 USD |
| Total liabilitiesBalance sheet | 947,981 USD | — | — | 637,856 USD | 637,856 USD | 804,966 USD | — | — |
| Capital expendituresCash flow statement | — | 575 USD | — | — | 36,971 USD | — | 35,994 USD | — |
| Financing cash flowCash flow statement | — | 73,316 USD | — | — | 298,841 USD | — | 32,297 USD | — |
| Investing cash flowCash flow statement | — | 402,152 USD | — | — | 944,751 USD | — | 950,468 USD | — |
| Operating cash flowCash flow statement | — | -570,162 USD | — | — | -1,838,382 USD | — | -2,799,444 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 04/14/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.